Technological Gaming in Cancer Survivors (WINNERS)
Launched by ANTONIO PÉREZ MARTÍNEZ · Mar 8, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The WINNERS trial is studying how playing specially designed video games can help improve brain function in children who have survived cancer. Many young cancer survivors experience long-term challenges with thinking and memory due to their treatments, and this study aims to see if these games can help boost their cognitive skills, as well as improve their overall well-being and immune system markers.
To participate, children aged 8 to 17 who completed their cancer treatment 1 to 6 years ago and received certain types of treatments that may affect the brain are eligible. Participants will be placed in either a group that plays the video games or a control group that does not. Throughout the study, researchers will measure changes in brain function and other health markers. Families can expect to see potential improvements not only in the children's cognitive abilities but also in their emotional health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between 8 and 17 years of age at the time of recruitment.
- • Have completed treatment between 1 and 6 years prior to recruitment.
- * Have had one of the following diagnoses:
- • Patients with CNS disease (posterior fossa tumors and supratentorial gliomas smaller than 1 cm affecting associative areas).
- • Patients with hematologic malignancies (leukemia or lymphoma).
- • Patients with solid tumors.
- • Patients with non-malignant hematological diseases and indication for allogeneic hematopoietic progenitor transplantation.
- * Having received at least one of the following treatments:
- • Central nervous system surgery.
- • Central nervous system radiotherapy.
- • Intrathecal/intraventricular chemotherapy.
- • Neurotoxic systemic chemotherapy.
- • Hematopoietic stem cell transplantation.
- • Informed consent signed by parent/guardian.
- Exclusion Criteria:
- • Active oncologic disease or relapse of active oncologic disease.
- * Prior neurological or psychiatric pathology that may preclude trial or treatment evaluations:
- • Psychological or neurocognitive illness or sequelae that preclude neuropsychological assessment or are expected to significantly artifact MRI results (examples: significant decrease in visual acuity, CNS surgical scar that artifacts imaging results, severe cognitive delay that precludes testing, etc.).
- • Psychological or neurocognitive illnesses or sequelae that prevent or contraindicate the use of video games (epilepsy that prevents the use of screens, significant decrease in visual acuity, etc.).
- • Mild or self-limiting neurological or psychiatric pathology that does not interfere with trial diagnosis and treatment (headache, epilepsy in remission with effective treatment, mild cognitive delay, etc.) will be allowed.
- • Current or recent (less than 1 year) use of other cognitive stimulation or brain training that may interfere with study results.
- • Refusal to abstain from the use of the study treatment games in case of being assigned to group B (control group).
- • Medical treatment that may significantly interfere with neuropsychological, imaging or biomarker assessments.
About Antonio Pérez Martínez
Antonio Pérez Martínez is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the pharmaceutical and biotechnology sectors, Mr. Pérez Martínez focuses on innovative therapeutic solutions and rigorous study designs. His expertise encompasses a wide range of therapeutic areas, ensuring that clinical trials are conducted with the highest ethical standards and scientific integrity. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, he aims to expedite the development of safe and effective treatments, ultimately enhancing the quality of care for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, Spain
Patients applied
Trial Officials
Antonio Pérez-Martínez, PhD
Principal Investigator
Hospital la Paz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported